Pabreca 125mg Capsule

About

Palbociclib is an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor, representing a targeted therapy used in the management of certain advanced breast cancers. Its mechanism of action involves selectively inhibiting CDK4 and CDK6, key enzymes that regulate cell cycle progression from the G1 phase to the S phase. By blocking these kinases, palbociclib prevents the phosphorylation of retinoblastoma protein (Rb), which in turn inhibits the release of transcription factors necessary for DNA synthesis and cell division. This leads to a G1 cell cycle arrest, effectively slowing the proliferation of cancer cells. It is typically used in combination with an aromatase inhibitor or fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, significantly improving progression-free survival in these patient populations.

Uses

• HR-positive, HER2-negative advanced breast cancer.
• HR-positive, HER2-negative metastatic breast cancer.
• In combination with an aromatase inhibitor as initial endocrine-based therapy.
• In combination with fulvestrant after disease progression on endocrine therapy.

Directions For Use

Take orally with food, preferably at the same time each day. Follow the prescribed dosage and schedule provided by your doctor.

Benefits

• Targets specific cancer cell pathways.
• Significantly improves progression-free survival.
• Effective in HR-positive, HER2-negative breast cancer.
• Can be combined with endocrine therapies.
• Oral administration for patient convenience.
• Offers a new treatment option for advanced disease.

Side Effects

• Neutropenia (low white blood cell count)
• Leukopenia (low total white blood cell count)
• Fatigue
• Nausea
• Stomatitis (mouth sores)
• Diarrhea
• Alopecia (hair loss)
• Anemia (low red blood cell count)
• Thrombocytopenia (low platelet count)
• Infections
• Vomiting
• Rash

Safety Measures

• Alcohol - Moderate alcohol consumption may be acceptable, but excessive intake should be avoided as it could exacerbate fatigue or gastrointestinal side effects.
• Pregnancy - Palbociclib can cause fetal harm. Women of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the last dose.
• Breastfeeding - It is unknown if palbociclib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 3 weeks after the last dose.
• Liver - Dose adjustments may be necessary for patients with moderate to severe liver impairment due to altered drug metabolism. Monitor liver function tests regularly.
• Kidney - Dose adjustments may be necessary for patients with severe kidney impairment. Monitor for adverse reactions and adjust dose as clinically indicated.
• Lung - Interstitial lung disease (ILD) and pneumonitis have been reported. Patients should be monitored for pulmonary symptoms, and treatment should be interrupted or discontinued if ILD is suspected.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.